Back to News
Market Impact: 0.12

Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Source: globenewswire.com

Healthcare & BiotechCompany Fundamentals
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study

Can-Fite BioPharma said it plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma. The update does not include efficacy, safety, or timeline specifics, so near-term read-through for outcomes appears limited.

AllMind Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request Trial

Market Sentiment

Overall Sentiment

neutral

Sentiment Score

0.05

Ticker Sentiment

CANF0.05

More News